Option 1
Ozempic / Wegovy (semaglutide)
GLP-1 receptor agonist; weekly injection.
Best for
Type 2 diabetes (Ozempic) + chronic weight management (Wegovy). The original.
Pros
- Longer track record (FDA-approved 2017)
- Stronger evidence base for cardiovascular protection
- Slightly cheaper than Mounjaro on some plans
- Available as oral formulation (Rybelsus)
Cons
- Average ~15% body weight loss in trials — less than tirzepatide's ~22%
- Same side effects (GI, fatigue, possible muscle loss)
- Same supply issues during shortages